Hind M. Almohanna , Azhar A. Ahmed , Jacob W. Griggs , Antonella Tosti
{"title":"Platelet-Rich Plasma in the Treatment of Alopecia Areata: A Review","authors":"Hind M. Almohanna , Azhar A. Ahmed , Jacob W. Griggs , Antonella Tosti","doi":"10.1016/j.jisp.2020.05.002","DOIUrl":"10.1016/j.jisp.2020.05.002","url":null,"abstract":"<div><p>Platelet-rich plasma (PRP) is an autologous preparation of plasma with concentrated platelets containing various growth factors and cytokines that enhance the body’s inherent capacity to repair and regenerate hair follicles. A few studies and case reports support the use of PRP for the treatment of alopecia areata (AA). Further large-scale studies are needed to evaluate the efficacy of PRP as monotherapy or in association with other therapeutic modalities for AA. Although PRP is relatively safe and potentially effective, there is no standardized protocol or recommendations for the number of PRP sessions required to treat and maintain hair growth.</p></div>","PeriodicalId":54791,"journal":{"name":"Journal of Investigative Dermatology Symposium Proceedings","volume":"20 1","pages":"Pages S45-S49"},"PeriodicalIF":0.0,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jisp.2020.05.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38628581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kathleen W. Wyrwich , Helen Kitchen , Sarah Knight , Natalie V.J. Aldhouse , Jake Macey , Fabio Nunes , Yves Dutronc , Natasha A. Mesinkovska , Justin M. Ko , Brett A. King
{"title":"The Role of Patients in Alopecia Areata Endpoint Development: Understanding Physical Signs and Symptoms","authors":"Kathleen W. Wyrwich , Helen Kitchen , Sarah Knight , Natalie V.J. Aldhouse , Jake Macey , Fabio Nunes , Yves Dutronc , Natasha A. Mesinkovska , Justin M. Ko , Brett A. King","doi":"10.1016/j.jisp.2020.05.006","DOIUrl":"10.1016/j.jisp.2020.05.006","url":null,"abstract":"<div><p>Meaningful patient input to understand disease experience and patient expectations for improvement with treatment is essential for the selection and development of outcome measures for alopecia areata (AA) clinical trials. This study explored the physical signs and symptoms of AA through 30 semistructured interviews with adult (n = 25) and adolescent (n = 5) patients experienced with severe or very severe AA. Scalp hair loss was overwhelmingly the most important sign and symptom of AA. Nearly all patients (90%) considered scalp hair loss in their top three most bothersome physical signs and symptoms of AA, with 77% (n = 23) naming scalp hair loss as the most bothersome symptom. Other identified signs and symptoms in the top three most bothersome included eyebrow, eyelash, nose, body, and facial hair loss, as well as eye irritation and nail damage and/or appearance. Eyebrow (16%, n = 4), eyelash (4%, n = 1), nasal (4%, n = 1), and body (4%, n = 1) hair loss were identified by seven adult patients as the most bothersome signs and symptoms of AA. Conceptual saturation confirmed that a comprehensive understanding of this patient population’s physical AA-related signs and symptoms was obtained. These findings indicate that the primary objective for new AA treatments for this patient population should be meaningful improvement in scalp hair growth to address the most troubling unmet need.</p></div>","PeriodicalId":54791,"journal":{"name":"Journal of Investigative Dermatology Symposium Proceedings","volume":"20 1","pages":"Pages S71-S77"},"PeriodicalIF":0.0,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jisp.2020.05.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38528082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Mouse Models of Alopecia Areata: C3H/HeJ Mice Versus the Humanized AA Mouse Model","authors":"Amos Gilhar , Rimma Laufer Britva , Aviad Keren , Ralf Paus","doi":"10.1016/j.jisp.2020.05.001","DOIUrl":"10.1016/j.jisp.2020.05.001","url":null,"abstract":"<div><p>The C3H/HeJ model has long dominated basic alopecia areata (AA) in vivo research and has been used as proof-of-principle that Jak inhibitors are suitable agents for AA management in vivo. However, its histologic features are not typical of human AA, and it is questionable whether it is sufficiently clinically predictive for evaluating the therapeutic effects of candidate AA agents. Instead, the humanized mouse model of AA has been used to functionally demonstrate the role of key immune cells in AA pathogenesis and to discover human-specific pharmacologic targets in AA management. Therefore, we advocate the use of both models in future preclinical AA research.</p></div>","PeriodicalId":54791,"journal":{"name":"Journal of Investigative Dermatology Symposium Proceedings","volume":"20 1","pages":"Pages S11-S15"},"PeriodicalIF":0.0,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jisp.2020.05.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38531236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Title Page with Sponsorship and Disclaimer Statements","authors":"","doi":"10.1016/S1087-0024(20)30024-1","DOIUrl":"10.1016/S1087-0024(20)30024-1","url":null,"abstract":"","PeriodicalId":54791,"journal":{"name":"Journal of Investigative Dermatology Symposium Proceedings","volume":"20 1","pages":"Page A3"},"PeriodicalIF":0.0,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1087-0024(20)30024-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47267010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A Botanical Compound for the Treatment of Alopecia Areata and Chemotherapy-Induced Alopecia","authors":"Bruce Patsner , Saad Harti","doi":"10.1016/j.jisp.2020.04.009","DOIUrl":"10.1016/j.jisp.2020.04.009","url":null,"abstract":"<div><p>Legacy Healthcare has developed and patented a topical botanical with a unique mechanism of action, an extensive clinical data package, and excellent safety from the 2.2 million units already sold, all of which has enabled it to enter late-stage clinical development for alopecia areata (AA), chemotherapy-induced alopecia, and soon female androgenetic alopecia. As this drug candidate is very safe, the European Medicines Agency agreed to Legacy Healthcare’s request to initiate late-stage clinical trial first in children, the neediest population suffering from AA. The initial trend from the phase II/III trial conducted to assess the efficacy and safety of the drug candidate in pediatric AA (RAAINBOW trial) looks promising, although no conclusions can be made. This drug candidate seems to offer several potential safety and economic advantages over other investigational synthetic and biologic compounds currently being investigated in populations with AA overall and especially for children.</p></div>","PeriodicalId":54791,"journal":{"name":"Journal of Investigative Dermatology Symposium Proceedings","volume":"20 1","pages":"Pages S69-S70"},"PeriodicalIF":0.0,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jisp.2020.04.009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38528081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Willingness to Pay and QOL in Alopecia Areata","authors":"Jean-Phillip Okhovat , Tristan Grogan , Lewei Duan , Carolyn Goh","doi":"10.1016/j.jisp.2020.05.003","DOIUrl":"10.1016/j.jisp.2020.05.003","url":null,"abstract":"","PeriodicalId":54791,"journal":{"name":"Journal of Investigative Dermatology Symposium Proceedings","volume":"20 1","pages":"Pages S60-S61"},"PeriodicalIF":0.0,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jisp.2020.05.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38528079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Natasha Mesinkovska , Brett King , Paradi Mirmirani , Justin Ko , James Cassella
{"title":"Burden of Illness in Alopecia Areata: A Cross-Sectional Online Survey Study","authors":"Natasha Mesinkovska , Brett King , Paradi Mirmirani , Justin Ko , James Cassella","doi":"10.1016/j.jisp.2020.05.007","DOIUrl":"10.1016/j.jisp.2020.05.007","url":null,"abstract":"<div><p>Previous QOL and disease burden studies have not captured all relevant aspects of living with alopecia areata (AA). To better understand the burden and everyday experience of living with moderate-to-severe AA, a cross-sectional, online, quantitative-qualitative survey was developed to assess symptoms, relationships, productivity, treatments, and financial burden. Adult patients were recruited from the National Alopecia Areata Foundation database. Data were analyzed descriptively. A total of 216 patients completed the survey. Most were female (83%), aged ≥45 years (59%), and white (78%). Nearly 2 of 3 respondents (62%) made different major life decisions (regarding relationships, education, or career) owing to AA. Most respondents (85%) stated coping with AA as a daily challenge, citing mental health issues, concealing hair loss, and others’ reactions; 47% reported anxiety and/or depression. Many patients (75%) persistently concealed hair loss (mean time spent, 10.3 h/wk). Treatment discontinuation was common owing to lack of efficacy, side effects, and cost. Associated expenditures included buying wigs or hairpieces and psychotherapy (mean ∼$2,000/y each). Survey respondents comprised a self-selected sample, which may not reflect the entire population. The impact of AA extends beyond cosmetic concerns and carries a considerable psychosocial burden. Efficacious, less burdensome AA treatments are needed to regrow hair and alleviate psychosocial sequelae.</p></div>","PeriodicalId":54791,"journal":{"name":"Journal of Investigative Dermatology Symposium Proceedings","volume":"20 1","pages":"Pages S62-S68"},"PeriodicalIF":0.0,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1087002420300174/pdfft?md5=0d1005dc3b2a539d696efadb94b5ad43&pid=1-s2.0-S1087002420300174-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38528080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Alopecia Areata: A Complex Cytokine Driven Disease","authors":"Teresa Song , Emma Guttman-Yassky","doi":"10.1016/j.jisp.2020.04.007","DOIUrl":"10.1016/j.jisp.2020.04.007","url":null,"abstract":"<div><p>Alopecia areata (AA) has been recently shown to also include T-helper cell type 2/IL-23 activation, in addition to T-helper cell type 1/IFN-skewing. The success of Jak inhibition together with IL-4Rα antagonism and limited response to IL-17A and PDE4 (protein) inhibition in AA are increasing our understanding of the complex immune interplay in AA. Trials testing targeted therapeutics are needed to further elucidate the pathogenic contribution of various cytokines.</p></div>","PeriodicalId":54791,"journal":{"name":"Journal of Investigative Dermatology Symposium Proceedings","volume":"20 1","pages":"Pages S55-S57"},"PeriodicalIF":0.0,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jisp.2020.04.007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38528076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}